CL2025000145A1 - Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas - Google Patents
Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estasInfo
- Publication number
- CL2025000145A1 CL2025000145A1 CL2025000145A CL2025000145A CL2025000145A1 CL 2025000145 A1 CL2025000145 A1 CL 2025000145A1 CL 2025000145 A CL2025000145 A CL 2025000145A CL 2025000145 A CL2025000145 A CL 2025000145A CL 2025000145 A1 CL2025000145 A1 CL 2025000145A1
- Authority
- CL
- Chile
- Prior art keywords
- n3pglu
- antibodies
- pharmaceutical solutions
- pharmaceutical
- solutions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263369033P | 2022-07-21 | 2022-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2025000145A1 true CL2025000145A1 (es) | 2025-05-30 |
Family
ID=87576063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025000145A CL2025000145A1 (es) | 2022-07-21 | 2025-01-16 | Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP4558166A1 (fr) |
| JP (1) | JP2025525587A (fr) |
| KR (1) | KR20250037554A (fr) |
| CN (1) | CN119604302A (fr) |
| AR (1) | AR129994A1 (fr) |
| AU (1) | AU2023309007A1 (fr) |
| CA (1) | CA3261418A1 (fr) |
| CL (1) | CL2025000145A1 (fr) |
| CO (1) | CO2025000508A2 (fr) |
| CR (1) | CR20250023A (fr) |
| DO (1) | DOP2025000005A (fr) |
| IL (1) | IL318102A (fr) |
| JO (1) | JOP20250013A1 (fr) |
| MA (1) | MA71558A (fr) |
| MX (1) | MX2025000820A (fr) |
| PE (1) | PE20250785A1 (fr) |
| TW (1) | TW202421188A (fr) |
| WO (1) | WO2024020470A1 (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
-
2023
- 2023-07-20 EP EP23755273.2A patent/EP4558166A1/fr active Pending
- 2023-07-20 CR CR20250023A patent/CR20250023A/es unknown
- 2023-07-20 CN CN202380055471.XA patent/CN119604302A/zh active Pending
- 2023-07-20 AU AU2023309007A patent/AU2023309007A1/en active Pending
- 2023-07-20 KR KR1020257005184A patent/KR20250037554A/ko active Pending
- 2023-07-20 MA MA71558A patent/MA71558A/fr unknown
- 2023-07-20 WO PCT/US2023/070540 patent/WO2024020470A1/fr not_active Ceased
- 2023-07-20 JP JP2025502865A patent/JP2025525587A/ja active Pending
- 2023-07-20 CA CA3261418A patent/CA3261418A1/fr active Pending
- 2023-07-20 PE PE2025000205A patent/PE20250785A1/es unknown
- 2023-07-20 IL IL318102A patent/IL318102A/en unknown
- 2023-07-21 TW TW112127310A patent/TW202421188A/zh unknown
- 2023-07-21 AR ARP230101919A patent/AR129994A1/es unknown
-
2025
- 2025-01-16 CL CL2025000145A patent/CL2025000145A1/es unknown
- 2025-01-17 CO CONC2025/0000508A patent/CO2025000508A2/es unknown
- 2025-01-20 MX MX2025000820A patent/MX2025000820A/es unknown
- 2025-01-20 DO DO2025000005A patent/DOP2025000005A/es unknown
- 2025-01-21 JO JOJO/P/2025/0013A patent/JOP20250013A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20250785A1 (es) | 2025-03-14 |
| DOP2025000005A (es) | 2025-02-28 |
| CO2025000508A2 (es) | 2025-02-04 |
| WO2024020470A1 (fr) | 2024-01-25 |
| JP2025525587A (ja) | 2025-08-05 |
| JOP20250013A1 (ar) | 2025-01-21 |
| CA3261418A1 (fr) | 2024-01-25 |
| AU2023309007A1 (en) | 2025-01-30 |
| CR20250023A (es) | 2025-02-17 |
| AR129994A1 (es) | 2024-10-23 |
| CN119604302A (zh) | 2025-03-11 |
| MA71558A (fr) | 2025-05-30 |
| TW202421188A (zh) | 2024-06-01 |
| MX2025000820A (es) | 2025-03-07 |
| IL318102A (en) | 2025-02-01 |
| KR20250037554A (ko) | 2025-03-17 |
| EP4558166A1 (fr) | 2025-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003290A1 (es) | Anticuerpos de unión a cd3. (divisional de solicitud 201900643) | |
| BRPI0410684A (pt) | uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença | |
| JOP20190155B1 (ar) | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم | |
| AR029619A1 (es) | Vacuna | |
| BR112018075222A2 (pt) | anticorpos anti-tnfrsf25 | |
| AR115721A1 (es) | Anticuerpos que comprenden un polipéptido insertado en la región marco 3 | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2021013491A (es) | Nuevas endolisinas de gardnerella y usos de las mismas. | |
| CL2023000853A1 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| BR112018067946A2 (pt) | formulações tópicas contendo ciclosporina e usos das mesmas | |
| AR121118A1 (es) | Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau | |
| UY33258A (es) | Proteinas de union a antigeno | |
| EP4566629A3 (fr) | Utilisation d'un échange de plasma à faible volume pour le traitement de la maladie d'alzheimer dans des stades précoces et intermédiaires | |
| MX2021011596A (es) | Compuestos y composiciones como moduladores de se?alizacion tlr. | |
| TWD207993S (zh) | 手錶 | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| CO2021011057A2 (es) | Composición cosmética/dermatológica | |
| CL2025000145A1 (es) | Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas | |
| MX2016005321A (es) | Glicoproteinas recombinantes y sus usos. | |
| WO2023081194A3 (fr) | Méthodes de traitement de la maladie d'alzheimer | |
| MX2022006674A (es) | Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas. | |
| BR112021016795A8 (pt) | Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint | |
| BRPI0412506A (pt) | células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos | |
| BR112016007430A2 (pt) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
| ECSP23082050A (es) | Acetato de acetil sh-hexapéptido-5 amida para su uso en el tratamiento de trastornos de la caída del cabello y como agente para el cuidado del cabello |